OSE Immunotherapeutics' Pegrizeprument (VEL-101) Receives FDA Orphan Drug Designation for Heart Transplant Rejection Prevention

Key Takeaways

• FDA grants Orphan Drug Designation to pegrizeprument (VEL-101) for preventing heart transplant rejection
• This is the second orphan designation for the drug, following liver transplant approval in January 2026
• Orphan status provides market exclusivity and development incentives for this rare disease treatment

---

Nantes, France – OSE Immunotherapeutics SA announced that its partner Veloxis Pharmaceuticals has received FDA Orphan Drug Designation for pegrizeprument (VEL-101) to prevent organ rejection in heart transplant patients.

Expanding Orphan Drug Portfolio

The designation marks the second orphan drug status granted to pegrizeprument in 2026, following January’s approval for liver transplant rejection prevention. This regulatory milestone positions the immunotherapy as a potential treatment across multiple organ transplant types.

Market Impact and Development Benefits

Orphan Drug Designation provides significant advantages including seven years of market exclusivity upon approval, tax credits for clinical development costs, and FDA fee waivers. For heart transplant patients, who number approximately 3,500 annually in the United States, new prevention options could address critical unmet medical needs.

The heart transplant market faces ongoing challenges with current immunosuppressive regimens, including long-term toxicity and incomplete rejection prevention. Pegrizeprument’s mechanism of action targets specific immune pathways involved in organ rejection.

Partnership Strategy

OSE Immunotherapeutics’ collaboration with Veloxis Pharmaceuticals demonstrates a strategic approach to rare disease drug development. Veloxis brings specialized expertise in transplant medicine and established relationships with transplant centers.

Clinical Development Timeline

While specific trial timelines weren’t disclosed, orphan drug designations typically accelerate development pathways. The FDA’s recognition of pegrizeprument’s potential across multiple transplant indications suggests strong preclinical data supporting its therapeutic promise.

The dual orphan designations position pegrizeprument as a potentially transformative therapy in transplant medicine, addressing critical needs in both heart and liver transplant populations.

---

Frequently Asked Questions

What does Orphan Drug Designation mean for heart transplant patients?

It means pegrizeprument has been recognized as addressing an unmet medical need for heart transplant patients, potentially leading to faster development and approval of a new treatment option.

When will pegrizeprument be available for heart transplant patients?

The timeline hasn’t been specified, but Orphan Drug Designation typically accelerates development. Clinical trials must still be completed before FDA approval.

How does pegrizeprument differ from current heart transplant rejection treatments?

While specific mechanisms weren’t detailed, pegrizeprument targets specific immune pathways and has shown enough promise to receive orphan status for multiple organ types, suggesting potential advantages over existing therapies.